ImmunityBio (IBRX) Preferred Stock Liabilities (2023 - 2026)

ImmunityBio (IBRX) has 4 years of Preferred Stock Liabilities data on file, last reported at $23.3 million in Q1 2026.

• On a quarterly basis, Preferred Stock Liabilities rose 13.49% year-over-year to $23.3 million in Q1 2026; TTM through Mar 2026 was $23.3 million, a 13.49% increase from a year earlier, with the FY2025 full-year figure at $19.7 million, down 24.49% from the prior year.
• Preferred Stock Liabilities for Q1 2026 stood at $23.3 million, up from $19.7 million in the prior quarter.
• Over the last five years, Preferred Stock Liabilities for IBRX reached as high as $37.9 million in Q1 2024 and fell as low as $18.3 million in Q3 2025.
• Historically, Preferred Stock Liabilities has averaged $24.0 million across 4 years, with a median of $20.7 million in 2024.
• Across the five-year window, Preferred Stock Liabilities tumbled 45.84% in 2025 and increased 13.49% in 2026, its largest moves.
• Year by year, Preferred Stock Liabilities stood at $35.3 million in 2023, then decreased by 26.07% to $26.1 million in 2024, then slipped by 24.49% to $19.7 million in 2025, then advanced by 18.21% to $23.3 million in 2026.
• Per Business Quant data, the three most recent Preferred Stock Liabilities figures were $23.3 million in Q1 2026, $19.7 million in Q4 2025, and $18.3 million in Q3 2025.